Introduction
As outlined in 2010 genetic 'year in a review' there are major impediments that hamper the detection of robust genetic signals in complex diseases such as osteoarthritis (OA): (1) The considerable genetic component in OA is most likely of a polygenic nature with modest effect sizes 1 which inevitably implies a comprehensive collaborative approach involving many cases and controls. ( 2) The large heterogeneity of the OA phenotype; occurring at specific joint locations, in a more generalized form or with and without clinical presentation each with their own heritability estimate. Furthermore, also in genetic studies there is lack of consensus on case and control definitions leading to misclassification within case and/or control groups and therewith a reduction of power. Despite these culprits, genetic studies up until now have provided a few compelling signals such as the 7q22 locus 2 containing multiple potential genes, the growth differentiation factor 5 (GDF5) gene 3, 4 , frizzled related protein (FRZB) gene 5 , the deiodinase, iodothyronine, type II (DIO2) gene 6 and the SMAD3 gene 7 (see also Table I ). These signals have been discovered by a combination of (discovery driven) genome wide scans and hypotheses driven candidate gene approaches. The latter depends on an educated guess in understanding the biological pathways leading to disease. Furthermore, it should be noted that the applied analyses (linkage and/or association) are depending on the expected penetrance of the gene variant and its frequency. When the expected penetrance is moderate to large, the variant frequency relative low and possibly heterogenic, linkage analyses are considered most appropriate. However, when the underlying rationale has a focus on the 'common disease, common variant' hypothesis, a genome wide association (GWA) study is most appropriate. It should be noted that because of this essential difference of the nature of the signal, the genes found through linkage are not necessarily replicated in GWA scans and vice versa (e.g., the FRZB gene 5, 8 ). This does not directly discard the initial results but merely reflects the fact that the different approaches are best suited to capture susceptibility genes from different ends of the complex genetic spectrum. The results depicted in Table I represent a typical mixture of such genetic findings reported up until 2010. At present, only two OA susceptibility signals (GDF5 and 7q22) meet the strict international criteria of genome wide significance, set at a P-value below 5 Â 10
À8
. The 7q22 locus contains six genes in a linkage disequilibrium block extending over 500 kb, none of which appeared as obvious OA candidate. On the other hand, the encoded protein of the GDF5 gene is a member of the bone morphogenetic protein (BMP) family and the TGF-beta super family. The role of GDF5 in the development and maintenance of bone and cartilage has been known for some time, however, the exact mechanism by which the recognized susceptibility single nucleotide polymorphism (SNP) rs143383 and rs143384 confer risk to OA remains to be elucidated. Such results present the typical problems that occur in the mapping of complex traits and expose the gap between genetic evidence and the molecular mechanism behind the disease. Now that several large consortia (such as TREATwOA arcOGEN) have been piling up GWAs data on OA to perform powerful meta-analyses and thus the discovery of additional robust OA associated SNPs with the expected small effect sizes is assured 9e12 , the need for functional pipelines to elucidate the underlying mechanism becomes imperative.
In summary, the OA genetic promises of 2011 were to address the clinical heterogeneity, to conduct additional powerful GWA scans with over 7,000 cases and controls and to perform functional follow up of current OA susceptibility loci to identify the underlying mechanisms. The following selection of subjects is based on the opinion of the author and has a focus on the discovery of genetic signals in OA etiology.
Phenotype heterogeneity
As indicated phenotypic heterogeneity in OA and the lack on consensus on case and control definition is considerably diluting power in GWA studies due to misclassification. In 2011, Kerkhof et al. 13 have attempted to minimize the differences in OA case and control definitions by putting forward, recommendations for standardization and phenotype definitions in genetic studies of OA. Applying stricter selection criteria to case and controls may result in more homogeneous subject thereby enhancing power.
Powerful GWA scans arcOGEN stage 1 and 2
At the OARSI 2011 the arcOGEN phase 2 meta analysis results were reported based on world wide OA studies containing a total of 7,410 knee and/or hip OA cases and 11,009 controls as follow-up of the first phase 1 . In total five loci showed association at the genomewide significance threshold (P < 5 Â 10 À8 ) albeit for different phenotypic OA strata: all combined, knee only, hip only, only in men or women. Since stratification by definition consumes power, this differentiated result typically reflects the clinical and genetic heterogeneity of the OA phenotype. The most highly associated SNP was found in the total joint replacement (TJR) analysis (P-value ¼ 7.2 Â 10 À11 ) for an SNP located at chr3p21.1, in a region encompassing a large number of genes. The other genome-wide significant signals were found at chromosomal regions containing genes with no known role in OA with the exception of a variant in CHST11 (chondroitin 4 sulfotransferase 11) gene associated with total hip replacement. This gene is reported to be important for chondrocyte development during cartilage morphogenesis 14 .
Although, substantial efforts are necessary to elucidate the underlying mechanisms of the discovered unknown OA susceptibility genes, they may provide new compelling insights in how OA arises.
arcOGEN 1000 genomes imputation
Recently, through a large scale next generation sequencing effort, the whole genome sequence of individuals of Caucasian origin have become publicly available 15 . This dataset can be used to infer a large numbers of additional genotypes in GWA studies through the identification of coinheritance patterns (haplotypes) on which low frequency SNPs reside. The application of these imputations to the OA genetic research holds the potential to discover genes and their rare variants that explain a much larger part of the heritability. Day-Williams et al. 16 reported on a genome wide significant result of SNP rs11842874 (minor allele frequency w0.07) with a combined odds ratio of 1.17 (95% confidence interval (CI) of 1.11e1.23) with P-value 2.13 Â 10 À8 within the MCF2L gene (MCF.2 cell-line-derived transforming sequence-like, encoding the guanine nucleotide exchange factor) which was found to be associated across a total of 19,041 OA cases and 24,504 controls of European descent. Although the SNP was already present on the original genotyping array, the MCF2L OA locus was taken forward on the basis of evidence accrued through imputation based on the 1000-genomes dataset which could not be observed with the initial imputation based on HapMap data. In human cells, MCF2L regulates neurotrophin-3-induced cell migration in Schwann cells, is a member of the nerve growth factor (NGF) family and is anticipated to play a role in OA through modulation of pain perception 16 .
The Rotterdam GWA study on joint space width (JSW)
Another possible enhanced use of GWA studies could be to explore the case distribution towards endophenotypes that represent different aspects of the complex OA disease phenotype as opposed to the traditional binomial distribution of cases and controls. A compelling example was presented at OARSI 2011 by Castano Betancourt et al. 17 concerning a genome wide association scans (GWAS) on quantitatively assessed minimal joint space width (mJSW) of the hip radiographs in a discovery sample of 6,523 participants from the Rotterdam Study I and II and with subsequent replication in a total of 4,443 individuals from three studies in the UK (Chingford, GOAL and TwinsUK). In the discovery cohort an SNP on chromosome 19 was found to be associated with JSW differences which replicated in an overall meta-analysis with a genome wide significant P value of 1.1 Â10
À11
. The minor allele, that associated with a larger joint space, was also associated with a decreased risk for hip OA (P-value ¼ 7 Â 10 À5 ) and consistently associated with mJSW in individuals without hip OA, suggesting that the effect is on cartilage thickness rather than degradation. The SNP is located in a gene that has recently been linked to Wntsignaling, and these results now suggest a role in chondrogenic differentiation. This example may soon be followed by other promising quantitative traits such as statistical shape models determining aspects of e.g., hip shape 18 or biochemical marker levels. Such analyses will additionally contribute to the understanding of pleiotropic aspects of OA as complex disease.
Candidate gene studies

COL11A1
Potential possibilities of these large consortia are to rerun dedicated analyses for a limited number of genes which e.g., represent a pathway likely to be involved in OA pathophysiology. A major advantage is that such a gene set analyses does not suffer from the penalty of performing over a million tests which applies to genome wide analyses. At OARSI 2011 Rodriguez-Fontela et al. 19 and Kerkhof et al. 20 each reported on gene set screen by means of a meta analysis across eight GWAS of the TREATwOA consortium with respectively, OA susceptibility genes and genes that are found to cause rare skeletal (dysplasia) syndromes. OA susceptibility genes were identified by a systemic screen in the HUGE Navigator with search terms OA, spinal osteophytosis and intervertebral disk with two independent SNPs that were not in linkage disequilibrium. COL11A1 is a minor fibrillar collagen which adds structure and strength to connective tissue and this collagen was also previously identified as potential OA susceptibility gene through the arcOGEN stage 1 GWA
1
. Despite the fact that the identified SNPs were not in linkage disequilibrium (LD) it should be noted that the three studies contain overlapping cases and controls and these associations may partly reflect the same signal. Irrespectively, these evidences could be considered a revival of COL11A1 as OA susceptibility gene and may justify additional investigation.
HLA locus on chromosome 6p
In 2010, a Japanese GWA study in 899 cases and 3,396 controls reported on two SNPs, located in a small region of the HLA locus, that associated to knee OA (Table II) 21 . Although this initial result in Japanese subjects reached genome wide significance (P-value of 6.7 Â 10 À8 ), the association appeared absent in a relative small European sample 21 . Subsequently, Shi et al. 22 reported on the absence of association in Han Chinese and more recently, a large scale European replication study also showed absence of association of the two SNPs across in 36,408 controls and 5,749 knee OA cases of European descent 22 . In the latter study, it was also shown that differences in linkage disequilibrium across the locus may be a possible explanation for this lack of replication 23 .
Functional follow up
Growth differentiation factor 5 (GDF5)
In early 2011, Daans et al. 24 reported on the haplo-insufficient GDF5 mice which didn't show developmental abnormalities, however, the genotype was shown to confer an increased risk to develop OA upon joint integrity challenges indicating for the first time in OA that subtle changes in gene expression in the target tissue throughout life could predispose to OA onset. Moreover, in 2011 the previously assessed imbalanced allelic expression of GDF5 in human joint tissues 25 was functionally explored in a study by Reynard et al. 26 . This study demonstrated that the differential allelic expression was modulated epigenetically by CpG sites in the promoter of the GDF5 gene. Subsequently, it was shown that the CpG sites formed by the presence of the C alleles at the susceptibility SNPs rs143383 and rs143384 were variably methylated and that treatment of a heterozygous cell line with a demethylating agent further increased the allelic expression imbalance between the C and T alleles. This study demonstrates compelling evidence that the genetic effect of the rs143383 SNP on GDF5 expression is modulated epigenetically by DNA methylation. The variability in the allelic expression balance of rs143383 is therefore partly accounted for by differences in DNA methylation, which in turn may influence the penetrance of this allele in susceptibility to common musculoskeletal diseases.
Chromosome 7q22 locus
The 7q22 locus contains six known genes in a linkage disequilibrium block extending over 500 kb: PRKAR2B, encoding protein kinase-cAMP-dependent-regulatory-type II-b; HPB1, encoding HMG-box transcription factor 1; COG5, encoding component of oligomeric golgi complex 5; GPR22, encoding an orphan G proteincoupled receptor 22; DUS4L, encoding dihydrouridine synthase 4-like and BCAP29, encoding B-cell receptor-associated protein 29 and none of these genes qualifies as an obvious OA candidate but all are expressed to lower or higher extent in either healthy or OA affected cartilage. At the OARSI 2011 results were presented on relevant functional aspects of the GPR22 locus in the mouse chondrogenic cell line ATDC5. The authors concluded that GPR22 plays a critical role in the fate of chondrogenic cells and points towards the hypertrophic switch observed in articular chondrocytes in the course of OA 27 .
Together the functional studies on GDF5 and GPR22 confirm the generally accepted expectation that imbalanced allelic expression and/or gene expression may be an important molecular mechanism underlying genetic predisposition of complex traits 28 .
Promise for 2012
As indicated in this review the major promise for 2011, being the generation of robust signals in GWA studies by the use of large numbers of cases and controls, are currently being granted. Details of these studies will most likely be published in the next 6 months and OA susceptibility SNPs within new genes and pathways will be elucidated. However, another part of these SNPs may be unknown, not be previously associated to OA, not be disease specific nor even be expressed in joint tissues. Efforts to uncover such novel players and to elucidate mechanisms of current OA susceptibility genes and pathways demands extensive functional genomic research (DNA and RNA) to relevant joint tissue (affected and preserved cartilage, subchondral bone, osteophytes ligaments), cell models (e.g., modulations of GPR22 expression in ATDC5 cells during chondrogenesis) and animal models (haplo-insufficient GDF5 mouse model).
Given the specific GWA approach taken, the identified SNPs will only have small effect sizes and therefore add only slightly to the total attributable genetic risk of OA. As with other complex diseases a major challenge that remains is to explain this so called "missing part" of the heritability. Hopes are high for deep sequencing approaches by applying next generation sequencing (whole genome, exome, and RNA-sequencing) to uncover additional rare genetic variation specific to OA susceptibility that may fill-in some of the heritability gap. We should, however, be aware that these approaches have, thus far, been successful mainly for disease gene discovery in more monogenic disorders resulting from private mutations with high penetrance 29 . Meanwhile, many efforts are undertaken to adapt the next generation sequencing approaches by exploring the extent to which rare alleles explain the heritability by means of calculating burden of rare variants in respective genes or genes in a pathways. A lot of work is, however, lying ahead to overcome the obvious power issues that such approaches suffer from 30 . 
